Adverum Biotechnologies, Inc. is the latest gene therapy player to feel the financial pinch but the US firm hopes a major restructuring will safeguard funds to advance its one-time wet age-related macular degeneration (AMD) treatment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?